Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
by Zacks Equity Research
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
by Zacks Equity Research
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
by Zacks Equity Research
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 163.83% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.28% and 1.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.75% and 1.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Ionis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
by Zacks Equity Research
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings
by Zacks Equity Research
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.